资料 | OncoC4

2025年05月30日

Phase 1 Study Of Gotistobart (BNT316/ONC-392) In Combination With Lutetium 177 VipivotideTetraxetan (Lu 177) In Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

2025年05月30日

Gotistobart In Combination With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On PD-1 Inhibitors With Or Without CTLA-4 Inhibitors

2025年01月13日

pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4antibodies

2024年09月15日

PRESERVE-004/GOG-3081 (NCT05446298): A Phase 2 randomized dose optimization trial of gotistobart, a pH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer

2024年07月19日

PRESERVE-004/GOG-3081 (NCT05446298): A Phase 2 randomized dose optimization trial of gotistobart, a pH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer

2024年07月19日

PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF GOTISTOBART + PEMBROLIZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER (PROC)

2024年01月04日

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

2023年11月01日

Single agent Safety and Activities of Target preserving Anti CTLA 4 Antibody Gotistobart (ONC 392/BNT316) in PD –(L)1 Resistant Metastatic NSCLC and Population PK Analysis in Patients with Solid Tumors

2023年09月22日

Preserving CTLA-4 Checkpoint Function for Safer and More effective Immunotherapy

2023年09月14日

Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4– and PD-1–targeted immunotherapy

2023年05月10日

Safety and Clinical Activity of Target Preserving Anti-CTLA-4 Antibody ONC-392/BNT316 as Monotherapy in NSCLC Patients who Progressed on PD-(L)1 targeting Immunotherapy

2023年05月10日

PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 /BNT316 Versus Docetaxel in Metastatic Non-Small Cell LungCancers that Progressed on PD-1/PD-L1 Inhibitors (NCT05671510)

2023年05月09日

CD24-Siglec interactions in inflammatory diseases

2022年11月08日

Safety and Clinical Activities of ONC-392, a target preservinganti-CTLA-4 mAb, in Ovarian Cancer Patients Who Have Failed Multiple Lines of Systemic Therapies

2022年11月08日

Dose escalation of ONC-392, a target preserving anti-CTLA4 mAb, in combination with fixed dose of pembrolizumab in patients with advanced solid tumors and dose expansion in patients with IO-resistant melanoma

2022年08月22日

CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder

2022年07月15日

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

2021年11月10日

Clinical protocol of an open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors

2021年11月10日

Pharmacokinetics of First and Repeated Dosing of Anti-CTLA-4 Monoclonal Antibody ONC-392 in Advanced Cancer Patients

2021年11月10日

First-in-human study of the first acid pH sensitive and recycling CTLA 4 antibody ONC392 that preserves the immune tolerance checkpoint to avoid immunotherapy related adverse events in patients with advanced solid tumor (PRESERVE 1, NCT04140526)

2021年11月10日

Molecular Insights on Safety and Anti-tumor Activity ofAnti-CTLA-4 Monoclonal Antibody ONC-392

2021年02月09日

Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma.

2020年07月30日

Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.

2020年04月01日

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.

2020年01月24日

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.

2020年01月01日

Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.

2019年08月01日

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.

2018年12月01日

How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

2018年04月01日

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.

2018年04月01日

Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice.

2014年09月01日

Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.

2014年08月14日

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.

2014年01月01日

Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.

2011年05月01日

Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.

2011年04月08日

Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

2011年02月01日

Sialoside-based pattern recognitions discriminating infections from tissue injuries.

2009年01月01日

CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.

2007年04月06日

A dinucleotide deletion in CD24 confers protection against autoimmune diseases.

2006年01月01日

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.

2005年01月01日

Anti-human CTLA-4 monoclonal antibody promotes T cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies.

2005年01月01日

Human CTLA-4-knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.

2003年12月09日

CD24 is a genetic modifier for risk and progression of multiple sclerosis.